K Reich
Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation® Center, Hamburg, Germany
A Blauvelt
Oregon Medical Research Center, Portland, Oregon, USA
M Lebwohl
Icahn School of Medicine at Mount Sinai, New York, New York, USA
KA Papp
Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada
P Rich
Oregon Dermatology and Research Center, Portland, Oregon, USA
B Strober
Yale University, New Haven, Connecticut, USA; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA
D De Cuyper
UCB Pharma, Brussels, Belgium
C Madden
UCB Pharma, Raleigh, North Carolina, USA
L Peterson
UCB Pharma, Raleigh, North Carolina, USA
V Vanvoorden
UCB Pharma, Brussels, Belgium
RB Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK
Keywords
Plaque Psoriasis, Biologic, Bimekizumab, Safety
References
1. Glatt S. Br J Clin Pharmacol 2017;83:991–1001
2. Papp KA. J Am Acad Dermatol 2018;79:277–86 e10.